Enzon Pharmaceuticals (NDAQ:ENZN) shareholders may soon be rewarded after a large shareholder expressed concerns regarding a “troubling disconnect” in the stock. DellaCamera Capital, which owns 5.2% of the company, requested that the company hire an advisor to analyze various financial and structural options and implement a cohesive financial plan of action that would deliver increased value to shareholders.

“In our opinion, Enzon’s current stock price of $9.75 represents a significant discount to the intrinsic value of the Company and in no way reflects the tremendous embedded optionality associated with Enzon’s R&D pipeline and technology platform,” said portfolio manager Richard Mansouri. “It is our belief that the corporate structure and operational complexity of Enzon have made it difficult for the investment community to accurately assess the inherent value of the Company.”

The activist hedge fund pointed out that a share price of $9.75 implies a shocking negative valuation of -$263.5 million for the company’s R&D operations that, in reality, show promise. Enzon has four products on the market that will generate an estimated $100 million in revenue in 2007. A reasonable sales multiple of 3.5x yields a value of $350 million for the marketed products alone. Add in the revenues from royalties and contracted manufacturing and you get an additional $440 million in value.

So, why is there such a value disconnect? Well, DellaCamera insists that it can be traced to the company’s complex structure. Currently, Enzon operates in two businesses: (1) a commercial business comprised of marketed products, royalties, and contract manufacturing; and (2)an R&D organization and technology platform. The profitability of the commercial operations is being completely obscured by the expenses associated with advancing the company’s clinical and pre-clinical trials. This complexity has also led to operating inefficiencies that have resulted in runaway expenses.

In the end, DellaCamera insists that the company should work to simplify its message to investors by consolidating its operations or taking other measures to unlock value. To this end, they requested that the company hire an advisor in order to explore the best options. Combined, these factors make ENZN a stock worth watching!

Related Companies
Amgen Inc. (AMGN)
Pfizer Inc. (PFE)
Merck & Co. (MRK)

The Cheesecake Factory (NDAQ:CAKE) shares spiked over ten percent today after Nelson Peltz's Star Trust revealed a ten percent stake in the company. The activist investor also requested and received early termination notice from the FTC, which is required under the Hart-Scott-Rodino antitrust law for the acquisition of stocks or assets greater than $50 million.

Nelson Peltz is well known for his activist involvement in companies like Wendy's International and H.J. Heinz Co., in which he was able to unlock substantial value for shareholders. The activist investor may see the Cheesecake Factory as a strong play in today's troubled markets. The company has shown consistent EPS growth with extremely strong financials.

So, is the Cheesecake Factory a bargain at these prices? Well, before today's move the stock was trading at just $22, which is about 17x next years estimated EPS. This is an extremely low P/E ratio that should stand around 25x, which would equate to a stock price of around $33 per share - or about 50% higher than it trades now.

In the end, this is a solid stock that is being acquired by an activist that has clearly indicated that he wants more. Whether or not Peltz plans on taking any actions to unlock value remains to be seen, but this is definitely a stock to watch in the meantime!

Related Companies
Grill Concepts, Inc. (GRIL)
Darden Restaurants Inc. (DRI)
Applebees International Inc. (APPB)

Total Systems Services, Inc. (NYSE:TSS) announced that its shareholders would receive $3.03 per share in connection with the company's nearly completed spin-off from parent Synovus Financial Corp. (NYSE:SNV). Shareholders applauded the spin-off and one-time dividend as effective methods for unlocking value in the company's hares.

Synovus shareholders will receive 0.484 shares of TSYS common stock for each share of Synovus stock in connection with the spin-off. Shareholders that hold fractional shares will receive cash for the fraction. TSYS shareholders on record as of December 17th will also receive a $3.03 all-cash one-time dividend on December 31st. Combined, these two actions will divest Synovus' 80.6% stake in TSYS and enable shareholders to realize value in both.

Spin-offs in general tend to outperform the overall market for several reasons. First, parent company shareholders are occasionally uninterested or unable to hold (mutual funds, for example) stock in the spin-off and therefore automatically sell. Secondly, the management team at a spin-off company are typically heavily incentivized to perform since it is a new company that is still well capitalized. And finally, pure-play assets are typically valued higher than conglomorate assets.

In the end, this is great news for Synovus shareholders and TSYS shareholders as they will likely see a significant appreciation in value over the next two years. Combined, these factors make TSS a stock worth watching closely!

Related Companies
Pegasystems Inc. (PEGA)
Fiserv Inc. (FISV)
Cash Technologies Inc. (TQ)